HOT HMV 2: A Phase 4 Study (HOT-HMV2)

Home Oxygen Therapy - Home Mechanical Ventilation 2: A Phase 4 Study

Smoking related lung disease or Chronic Obstructive Pulmonary Disease (COPD) is characterised by periods of worsening symptoms termed exacerbations. In some patients these may be severe enough to require hospitalisation and support for their breathing. Patients who suffer a severe exacerbation requiring breathing support using mask ventilation (also termed non-invasive ventilation, NIV) have a high chance of being readmitted to hospital in the following 12 months. Recent evidence suggests that the provision of a breathing machine at home (home mechanical ventilation, HMV) may reduce the risk of readmission to hospital in selected patients.

Morbidity and mortality in the 12 months following a life-threatening exacerbation of COPD remain high. Recent data from the Lane Fox Clinical Respiratory Physiology Research Centre supports the addition of home non-invasive ventilation to standard care to improve admission-free survival in patients with persistent hypercapnia following a decompensated exacerbation of COPD.

The study is designed to evaluate the clinical implementation of the delivery of home non-invasive ventilation in COPD patients with persistent hypercapnia following an acute exacerbation of COPD to validate that the clinical benefit derived from the HOT-HMV trial is maintained when the home non-invasive ventilation is implemented into routine clinical practice.

Study Overview

• Status: Completed
• Conditions: COPD Exacerbation
• Intervention / Treatment: Other: Observational Group

Detailed Description

Following publication of the home oxygen therapy-home mechanical ventilation (HOT-HMV) trial, the purpose of this study is to evaluate the clinical service delivery of home non-invasive ventilation (NIV) therapy in patients who have recently undergone, and recovered, from a life-threatening exacerbation of COPD.

This prospective cohort observational study is designed to evaluate the clinical implementation of the delivery of home non-invasive ventilation in COPD patients with persistent hypercapnia following an acute exacerbation of COPD to validate that the clinical benefit demonstrated by the HOT-HMV trial is maintained when the home non-invasive ventilation is incorporated into routine clinical practice.

Patients who have an admission to hospital with an acute exacerbation of COPD requiring non-invasive ventilation will be referred for assessment. Eligible patients will be referred by the critical care or appropriate respiratory team to a monthly assessment clinic for assessment of chronic hypercapnia. The total UK sample size will be 200 participants. St Thomas' critical care unit managed between 80-100 patients per year with non-invasive ventilation for life threatening exacerbation of COPD. This study will run over 4 years; therefore it is anticipated that 200 patients will be enrolled into the trial over this period. Patients will also be referred from peripheral hospitals to the Lane Fox Unit as a regional centre for home ventilation.

• Study Type: Observational
• Enrollment (Actual): 13

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, SE1 7EH
    • Guys and St Thomas NHS Foundation

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients who have an admission to hospital with an acute exacerbation of COPD requiring non-invasive ventilation will be referred for assessment. Eligible patients will be referred by the critical care or appropriate respiratory team to a monthly assessment clinic for assessment of chronic hypercapnia.

Description

Inclusion Criteria:

• Patient suspected or with proven diagnosis of COPD
• Admission to hospital with life-threatening exacerbation of COPD requiring acute NIV (at admission evidence of decompensated Chronic Respiratory Insufficiencies (PaCO2 > 6kPa, pH <7.35)
• Arterial partial pressure of carbon dioxide (PaCO2) > 6kPa at discharge from hospital
• Discharge from hospital without combined home non-invasive ventilation and home oxygen therapy
• Patient willing to consider home non-invasive ventilation in addition to home oxygen therapy
• Patient suitable for home oxygen therapy (appropriate risk assessment)

Exclusion Criteria:

• Patient already established on home non-invasive ventilation and home oxygen therapy
• Patient unable to support home non-invasive ventilation e.g. unable to apply mask, lacking social support
• Patient on palliative care pathway
• Patient outside of usual catchment area for Lane Fox Respiratory Service

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
12 month admission free survival	How many patients were not admitted to hospital during the 12 months following initiation of NIV and still alive	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Barriers to receiving HOT-HMV treatment	Evaluating what are the barriers for patients to receive HOT HMV treatment within a clinical service	12 months
What proportion of patients receive HOT-HMV as a proportion to those who received NIV acutely	Evaluating the proportion of patients who received NIV acutely vs those who are eligible to receive HOT HMV from the clinical service	12 months
What proportion of patients receive HOT-HMV as a proportion to those who are elgible to received HOT HMV	Evaluating the proportion of patients are eligble to receive HOT HMV vs those who actually receive HOT HMV from the clinical service	12 months
Cost of the clinical time and input to set patients up onto HOT HMV	What does it cost to set someone up onto HOT HMV	12 months
Length of clinical time taken to set patients up onto HOT HMV	How long does it take a clinician to set someone up onto HOT HMV	12 months
Report the clinical pathway and structure to deliver HOT HMV clinically	Establish a detail report outlining the clinical pathway and structure required of the clinical team to deliver HOT HMV clinically	12 months
Machine malfunction and failure	Determine the reliability of the NIV machines issued clinically by monitoring their malfunction and failure rates	12 months
Re admission to hospital	How many patients are readmitted to hospital within 28 days from set up onto HOT HMV	28 days
Tolerability of HOT HMV: How patients perceive they are tolerating the HOT HMV	How patients perceive they are tolerating the HOT HMV	12 months
Patients Quality of Life	Patients health related QoL by completing the Severe Respiratory Insufficiency questionnaire (SRI)	6 weeks, 3 months, 6 months and 12 months
Patients Quality of Life	Patients health related QoL by completing the COPD assessment test (CAT).	6 weeks, 3 months, 6 months and 12 months
Adherence to HOT HMV	Patients Adherence to their HOT HMV prescription taken from the datacard in their machine	6 weeks, 3 months, 6 months and 12 months

Collaborators and Investigators

• Sponsor: Guy's and St Thomas' NHS Foundation Trust
• Investigators: Study Chair: Nick Hart, MD, Guys & St Thomas NHS Foundation Trust

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2018
• Primary Completion (Actual): April 30, 2021
• Study Completion (Actual): April 30, 2021

Study Registration Dates

• First Submitted: February 10, 2020
• First Submitted That Met QC Criteria: February 14, 2020
• First Posted (Actual): February 17, 2020

Study Record Updates

• Last Update Posted (Actual): October 1, 2021
• Last Update Submitted That Met QC Criteria: September 30, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: 228411

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No